See more : Troika Media Group, Inc. (TRKA) Income Statement Analysis – Financial Results
Complete financial analysis of HilleVax, Inc. (HLVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HilleVax, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bytes Technology Group plc (BYIT.L) Income Statement Analysis – Financial Results
- SMA Solar Technology AG (SMTGY) Income Statement Analysis – Financial Results
- Aurora Labs Limited (A3D.AX) Income Statement Analysis – Financial Results
- Red Robin Gourmet Burgers, Inc. (RRGB) Income Statement Analysis – Financial Results
- W. R. Berkley Corporation (0HMZ.L) Income Statement Analysis – Financial Results
HilleVax, Inc. (HLVX)
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 2.25M | 3.00K | 0.00 | 0.00 |
| Gross Profit | -2.16M | -2.25M | -3.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 106.68M | 45.91M | 10.01M | 0.00 | 0.00 |
| General & Administrative | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 632.37K |
| SG&A | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Other Expenses | 0.00 | -94.70M | -20.23M | -779.00K | 0.00 |
| Operating Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Cost & Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Interest Income | 9.71M | 3.88M | 2.84K | 29.00 | 9.00 |
| Interest Expense | 2.39M | 3.41M | 2.84M | 29.00K | 9.00K |
| Depreciation & Amortization | 879.00K | 2.25M | 3.00K | 1.30M | 633.00K |
| EBITDA | -132.47M | -65.11M | -99.56M | -2.07M | -31.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -133.35M | -65.11M | -53.43M | -1.30M | -633.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.78M | -94.70M | -48.98M | -808.00K | -40.00K |
| Income Before Tax | -123.57M | -159.81M | -102.41M | -2.10M | -673.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 97.20M | -17.38M | 29.00K | -633.00 |
| Net Income | -123.57M | -257.01M | -85.03M | -2.13M | -673.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| EPS Diluted | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| Weighted Avg Shares Out | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
| Weighted Avg Shares Out (Dil) | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California...
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...
HilleVax to Participate in November Investor Conferences
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the...
3 IPO Stocks That You Want to Own
This down market is giving us some really intriguing stocks at cheap prices.
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's...
Biotech Public Offerings at 10-Year Low
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk...
Source: https://incomestatements.info
Category: Stock Reports